True North Therapeutics Report issue

For profit Phase 1
Founded: South San Francisco CA United States (2013)
Status: Acquired by Bioverativ Therapeutics Inc. (2017) → now Sanofi-Aventis (2018)

Organization Overview

First Clinical Trial
2015
NCT02502903
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 1 Trials (1)

tnt009 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Hemolytic (Phase 1)

Anemia, Hemolytic, Autoimmune (Phase 1)

Kidney Failure, Chronic (Phase 1)

Pemphigoid, Bullous (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1